GE Healthcare
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, GE Healthcare sits in the top decile of US sponsors by registered trial count (#242 of 15,742 sponsors by registered trial count).
GE Healthcare: 99 sponsored US clinical trials, 8 recruiting.
GE Healthcare sponsors 99 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 61 completed. 23 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 2 trials.
Top-decile sponsor footprint
GE Healthcare ranks in the top decile of sponsors by registered trial count (#242 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
61 of 90 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (67.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
99 total, page 2 of 2
Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)
NCT01952678
Clinical Evaluation for General Electric (GE) CT System
NCT01909180
Magnetic Resonance Imaging Using Innovative Pulse Sequences
NCT01724216
Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers
NCT01672996
SpO2 System Accuracy Testing With Different Sensors
NCT01613222
B40 Non-Invasive Blood Pressure Equivalency Study
NCT01546285
DXA Precision and Accuracy Comparison Study
NCT01530477
Accuracy Study of a Non-Invasive Blood Pressure Cuff in Comparison to an Invasive Radial Arterial Blood Pressure
NCT01485120
SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm Enhancement
NCT01482325
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
NCT01475097
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice
NCT01431378
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
NCT01440517
Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease
NCT01394926
Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
NCT01376089
Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
NCT01265394
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
NCT01252810
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
NCT01176513
NICU-TECH RM9L-RS Probe ME Feasibility Study
NCT01181596
Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels
NCT01165554
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer
NCT01303419
Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
NCT01092546
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System
NCT01076296
Trial of Yellow Fever Inactivated Vaccine
NCT00995865
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
NCT01028053
Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat Tool
NCT00987298
PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
NCT01053312
Prevalence of Sleep Disordered Breathing
NCT01011647
Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)
NCT01004770
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
NCT00918281
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
NCT00908310
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
NCT00878878
Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care
NCT00783302
Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
NCT00785044
A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
NCT00730964
Comparative Study of Phototherapy for Hyperbilirubinemia
NCT00635375
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
NCT00565721
Testing Digital Breast Tomosynthesis vs. Regular Mammogram in Detecting Breast Cancer in Women Having Screening Mammogram
NCT00535678
Perfusion Imaging and CT -Understanding Relative Efficacy
NCT00486447
Noninvasive Blood Pressure Monitor Evaluation Including Performance During Dysrhythmias
NCT00443001
A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms
NCT00382967
Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches
NCT00381316
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
NCT00348608
A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain
NCT00348569
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
NCT00335335
A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT
NCT00350506
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
NCT00126412
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
NCT00126425
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
NCT00126438
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography
NCT00209417
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 10 |
| Phase 3 | 12 |
| Phase 4 | 11 |
Where GE Healthcare enrollment is open (later-stage tilt)
8 recruiting of 99 indexed (8% open); 61 completed (62%).
Phase mix: 23 late (III/IV) vs 14 early (I/II) (later-stage heavy).
Top condition: Breast Cancer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
GE Healthcare: open-pipeline peers nationwide
Peers matched on 99 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
GE Healthcare sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 99 trials (± recruiting share)
- UCB Pharma · 100 trials · 0% recruiting
- Wake Forest University · 100 trials · 7% recruiting
- Creighton University · 98 trials · 5% recruiting
- Spaulding Rehabilitation Hospital · 101 trials · 19% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Oregon Research Institute · 8% recruiting · 62 trials
- National Eye Institute (NEI) · 8% recruiting · 221 trials
- Arcutis Biotherapeutics · 8% recruiting · 25 trials
- Medtronic Endovascular · 8% recruiting · 25 trials
Related
What to do with this GE Healthcare page
99 registered trials is a research-attention snapshot, not an endorsement of GE Healthcare or any single study.
- 8 of GE Healthcare's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition GE Healthcare studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. GE Healthcare pipeline card: 99 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.